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INTRODUCTION
Melanoma is the most aggressive type of
skin cancer. It is the seventh most com-
mon type of cancer among men and the
eighth most common among women with
a lifetime risk about 2% (Feng et al., 2011).
The incidence of melanoma is rising faster
than that of any other cancer type in the
US (Tsao et al., 2004). Melanoma is a
multifactorial disease whose risk depends
on genetic susceptibility (around 10% of
melanoma cases have a family history of
the disease) as well as on external fac-
tors, among which an exposure to ultravi-
olet (UV) radiation and sunburn play an
important role.
Brainmetastases is a major challenge in
melanoma and one of the least understood
aspects of this disorder (Skibber et al.,
1996; Fidler et al., 1999). Average survival
in advanced metastatic melanoma is only
6–10 months with <5% of patients liv-
ing 5 years after diagnosis (Jemal et al.,
2002). More than half of all melanoma
deaths occur from brain metastasis. A
key event in brain metastasis is the
migration of cancer cells through the
blood brain barrier (BBB) (Arshad et al.,
2010). The BBB is formed by special-
ized endothelial cells lining capillaries in
the central nervous system. Brain capil-
lary walls are more difficult to penetrate
due to a tight layer of endothelial cells,
tight junctions (TJs), and other struc-
tures that restrict the diffusion of micro-
scopic objects (e.g., bacteria) and large
or hydrophilic molecules into the cere-
brospinal fluid.
In order to allow the melanoma cell
to metastasize into the brain, the integrity
of the BBB has to be compromised. This
suggests that some germ line mutations
contributing to metastatic melanoma may
also increase the permeability of the BBB.
Finding such mutations and understand-
ing the mechanisms of their action could
make substantial contributions to reduc-
ing mortality from melanoma. Currently,
very little is known about the molecular
mechanisms by which melanoma cells can
penetrate the BBB.
The literature on germ line mutations
contributing to melanoma and its metas-
tases provides some clues about relevant
genes and their functions. Udart et al.
(2001) gave evidence that a number of
genes which are likely to play a role in
melanoma and metastases are located
on chromosome 7. The list includes
the EGFR gene encoding the epider-
mal growth factor receptor; the BRAF
gene, which is a member of the Raf
kinase family of serine/threonine-specific
protein kinases involved in the MAP
kinase/ERKs signaling implicated in
many cancers (Wangari-Talbot and Chen,
2012); the PDGF-A gene encoding for
platelet-derived growth factor alpha; the
PAI-1 encoding for plasminogen activator
inhibitor type 1; theMET proto-oncogene,
encoding for a membrane receptor pro-
tein with tyrosine–protein kinase activity,
and others. The PDGF-A is expressed in
primary and malignant melanoma and
might function as an autocrine growth
factor as well as an angiogenesis fac-
tor in tumor development. The PAI-1 is
expressed in highly invasive metastatic
human melanoma cell lines. The EGFR
gene and the MET gene were indepen-
dently amplified in human glioma. In
malignant melanoma, the MET gene
was shown to be expressed in metastatic
lesions.
The permeability of this BBB is essen-
tially regulated by TJ, the intercellular
junction, in which the outer cell mem-
branes are joined tightly together by rows
of membrane proteins. TJ regulates the
flow of ions, nutrients, and cells into the
brain (Dejana, 2004; Abbott et al., 2006).
The germ line mutation in genes involved
in TJ regulation could disrupt BBB func-
tioning. A number of recent studies
strongly support the connection between
melanoma metastasizing and TJ desta-
bilization (Leotlela et al., 2007; Fazakas
et al., 2011; Jayagopal et al., 2011). The
important components of TJ are a family
of proteins called “claudins.” Twenty-four
such proteins are currently known. Genes
CLDN2, CLDN3, CLDN4, CLDN11CL,
CLDN12, CLDN14, and CLDN15 encod-
ing for different claudins are also located
on the chromosome 7 (Paperna et al.,
1998; Hillier et al., 2003; Lal-Nag and
Morin, 2009). One more TJ gene on
chromosome 7 is OCLN, encoding for
“occludin” protein. The localization of all
these genes on one chromosome indicates
that these genes together with other (not
yet detected) genes on the same chromo-
somemight represent an important part of
the genetic mechanism linking the devel-
opment of melanoma and brain metas-
tases. If so, then performing association
study of melanoma using SNP data from
chromosome 7, and investigating func-
tions of corresponding genes, may provide
important insights about biological mech-
anisms connecting melanoma and brain
metastases.
DATA FROM LONG LIFE FAMILY STUDY
SUPPORT THE IDEA ABOUT ROLE OF
PLEIOTROPIC GENES IN MELANOMA
BRAINMETASTASES
The Long Life Family Study (LLFS)
involves four field centers (Boston, New
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York, and Pittsburg in the USA and
Denmark in Europe). The recruitment and
enrollment were conducted between 2006
and 2009. Potential probands were identi-
fied via Medicare enrollee, Danish Social
Register lists, and articles appearing on
the internet. Altogether, the LLFS enrolled
583 families with 1493 probands and their
siblings and 192 spouses in the older gen-
eration, 2437 offspring and 809 of their
spouses. The analyses did not include indi-
viduals with missing data on prevalence
of melanoma or observed covariates. The
remaining sample included 4638 individ-
uals; 110 (2.4%) of them have prevalent
melanoma. Among those, there were 2551
females [51 (2%) with melanoma] and
2087 males [59 (2.8%) with melanoma].
The tag SNPs for LLFS were produced by
running HaploView with windows of size
of 2000 markers at a time and r2 = 0.8.
These markers were used in the LLFS
principal component analyses (PCA). Tag
SNPs were calculated for SNPs with
MAF ≥ 5%; HWE p-value ≥ 1E-6.
The association study of this disease
used LLFS data and tag SNPs located
on chromosome 7. The prevalence of
melanoma among the LLFS participants
was considered as phenotype of inter-
est. Note that according to SEER data the
lifetime risk of melanoma is about 2%.
Assuming that the genetic variant we are
looking for is responsible for not more
than 75% of melanoma cases and the
lower boundary for a penetrance function
corresponding to genetic variant asso-
ciated with melanoma is not <0.1 the
genetic frequency of the corresponding
gene should not exceed 15%. The p-value
threshold correcting for multiple testing
was 1.7E-5. We used the EMMAX soft-
ware package which allowed us to evaluate
relatedness among family members using
SNP data and take it into account in the
analyses of family data (Kang et al., 2010).
Observed covariates included gender, field
center, generation (probands/offspring),
and smoking habit (ever or never smoked).
Twenty principal components were
used to control for possible population
stratification.
The analyses resulted in one genetic
variant reaching chromosome-wide level
of significance. The minor allele (T) of
the rs208353 SNP was found to be asso-
ciated with melanoma (p = 7.07E-6).
Note that the estimate of MAF of this
allele is about 7% which is in agree-
ment with the assumption of MAF< 15%
used in calculation of p-value threshold.
The detected rs208353 SNP is located
in the intron region of the GNA12
gene (synonyms: GNA12 |MGC104623
|MGC99644 |NNX3 |RMP | gep), which
encodes guanine nucleotide binding pro-
tein (G protein) alpha 12. This finding
supports recent result of Cardenas-Navia
et al. (2010) who found that GNA12 and
six other G-protein genes are frequently
mutated in melanoma (somatic muta-
tions). The literature review showed that
the GNA12 gene plays a critical role in
regulating TJ, which in turn is an essen-
tial component of the BBB permeability.
The loss of endothelial TJ function was
suggested to be an important event in
the disruption of the BBB and promot-
ing tumor metastases (Förster, 2008; Feng
et al., 2011). The role of GNA12 is not lim-
ited to its involvement in melanoma and
corresponding brain metastases. Several
studies demonstrated the involvement
of GNA12 in other cancers, potentially
through compromised regulation of TJ
and BBB permeability in carriers of some
variants of this gene. Meyer et al. (2003)
have shown that GNA12 directly affects
Zona-Occludens proteins (ZO-1) and
(ZO-2) which are usually localized at sites
of intercellular junctions. It also interacts
with the Src gene. ZO-1, ZO-2, and Src
genes are involved in cancer growth and
metastasis (Kaihara et al., 2003; Satomi
et al., 2011; Creedon and Brunton, 2012).
Sabath et al. (2008) have shown that TJ
can be disrupted by GNA12-stimulated
Src phosphorylation of ZO-1 and ZO-
2 (TJP2). Kumar et al. (2006) and Kelly
et al. (2006, 2007) demonstrated the
ability of GNA12 to promote neoplas-
tic transformations. Gan et al. (2011)
showed that GNA12 is over-expressed
in oral squamous cell carcinoma, and
the over-expression drives migration and
invasion of oral cancer cells. Juneja and
Casey (2009) provided evidence that the
G12 subfamily has been implicated in
cancer cell invasion and metastasis. G12
signaling promotes prostate, breast, and
ovarian cancer cell invasion in vitro, and
these proteins are highly expressed in
metastatic cancer tissues. Other genes
that interact with GNA12 include tumor
suppression gene TP53 and TJ gene TJ1.
GNA12 also influences non-cancerous
health disorders, such as ulcerative col-
itis and depression (Anderson et al.,
2011; Lees et al., 2011; Zhang et al.,
2012).
Thus, the GNA12 has pleiotropic health
effects. Its germline variants have been sig-
nificantly associated with melanoma in the
LLFS data; it was also detected in an inde-
pendent study of somatic mutations in
melanoma (Cardenas-Navia et al., 2010); it
is involved in TJ regulation important for
permeability of BBB; and it plays role in
many cancers as well as some other health
disorders.
The variant from chromosome 7
next most significantly associated with
melanoma in the LLFS data is the minor
allele (T) of the rs55750236 SNP located in
the KIAA1549 gene. Despite the fact that
the p-value (p < 8.7E-5) of this analysis
slightly exceeded the chromosome-wide
significance level, this association is likely
to be true positive. The KIAA1549 gene
is known for its fusion with BRAF gene
involved in the MAPK/ERKs signaling
pathway which is thought to play a piv-
otal role in melanoma as well as other
cancer development (Dahiya et al., 2012;
Lin et al., 2012; Wangari-Talbot and Chen,
2012; Lewis et al., 2013). The KIAA1549-
BRAF fusion itself was implicated in brain
tumors (Badiali et al., 2012; Lin et al.,
2012).
The analysis described above does not
preclude association studies of melanoma
using genetic variants located on other
chromosomes. Several melanoma-related
genes were found on other chromosomes,
including G-protein-coupled receptors
(e.g., GRM1) that are also involved in
brain function (see, e.g., Wangari-Talbot
and Chen, 2012). Thus, additional studies
are needed to develop a more complete
picture of genetic mechanisms connecting
melanoma and brain metastases, as well
as connecting the pathological effects of
genes located on different chromosomes.
The benefit of focusing on chromosome
7 is related to the specific research ques-
tion addressed in this paper exploiting
the fact that quite a number of genes
involved in melanoma development and
BBB regulation are located in this part
of the genome. Another benefit deals
with a smaller number of hypotheses
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testing in a genetic association study
that substantially reduces the number of
false positives compared to the genome
wide association study dealing with SNPs
from the entire genome. The important
finding of this study is that mutation
in the GNA12 gene can influence both
the development of melanoma and the
permeability of the BBB, and thereby con-
tribute to the progression of melanoma
to its metastatic state. The results of this
paper also indicate the important role of
genetic variants with pleiotropic effects
in the developing of multiple health dis-
orders. Recently, Jornsten et al. (2011)
used data on glioblastoma available at
The Cancer Genome Atlas (TCGA) to
construct network models of mRNA
expression. They found that the GNA12
gene is involved in network of disease-
relevant hub genes that influence patient
survival. The data on Skin Cutaneous
Melanoma were just recently included into
TCGA, so this resource can be used in the
near future to validate roles of pleiotropic
effects of genes in melanoma metastases.
Targeting the pleiotropic genes could be
an efficient strategy for simultaneous pre-
vention and treatment of many health
conditions.
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